NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 17, 2025
NRx Pharmaceuticals (NRXP) has announced it will release its fourth quarter and full year 2024 financial results before market opening on March 17, 2025. The clinical-stage biopharmaceutical company will follow the release with a conference call and corporate update at 8:30am ET.
The financial results will be accessible via press release on the company's investor relations website. Interested parties can join the conference call through a live webcast or by telephone, with domestic callers using +1-800-717-1738 and international callers using +1-646-307-1865.
NRx Pharmaceuticals (NRXP) ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 prima dell'apertura del mercato il 17 marzo 2025. La società biofarmaceutica in fase clinica seguirà il rilascio con una chiamata in conferenza e un aggiornamento aziendale alle 8:30 ET.
I risultati finanziari saranno accessibili tramite comunicato stampa sul sito web delle relazioni con gli investitori della società. Le parti interessate possono partecipare alla chiamata in conferenza tramite un webcast dal vivo o per telefono, con i chiamanti nazionali che utilizzano +1-800-717-1738 e i chiamanti internazionali che utilizzano +1-646-307-1865.
NRx Pharmaceuticals (NRXP) ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 antes de la apertura del mercado el 17 de marzo de 2025. La compañía biofarmacéutica en etapa clínica seguirá la publicación con una llamada de conferencia y una actualización corporativa a las 8:30 a.m. ET.
Los resultados financieros serán accesibles a través de un comunicado de prensa en el sitio web de relaciones con inversores de la empresa. Las partes interesadas pueden unirse a la llamada de conferencia a través de una transmisión en vivo o por teléfono, con los llamantes nacionales utilizando +1-800-717-1738 y los llamantes internacionales utilizando +1-646-307-1865.
NRx Pharmaceuticals (NRXP)는 2024년 4분기 및 연간 재무 결과를 2025년 3월 17일 시장 개장 전 발표할 것이라고 발표했습니다. 임상 단계의 생명공학 회사는 발표 후 오전 8시 30분 ET에 콘퍼런스 콜과 기업 업데이트를 진행할 예정입니다.
재무 결과는 회사의 투자자 관계 웹사이트를 통해 보도 자료로 접근할 수 있습니다. 관심 있는 분들은 생중계 또는 전화로 콘퍼런스 콜에 참여할 수 있으며, 국내 전화는 +1-800-717-1738, 국제 전화는 +1-646-307-1865를 사용하시면 됩니다.
NRx Pharmaceuticals (NRXP) a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 avant l'ouverture du marché le 17 mars 2025. La société biopharmaceutique en phase clinique suivra la publication d'une conférence téléphonique et d'une mise à jour de l'entreprise à 8h30 ET.
Les résultats financiers seront accessibles via un communiqué de presse sur le site Web des relations avec les investisseurs de la société. Les parties intéressées peuvent rejoindre la conférence téléphonique via un webinaire en direct ou par téléphone, les appelants nationaux utilisant le +1-800-717-1738 et les appelants internationaux le +1-646-307-1865.
NRx Pharmaceuticals (NRXP) hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 vor Markteröffnung am 17. März 2025 veröffentlichen wird. Das biopharmazeutische Unternehmen in der klinischen Phase wird der Veröffentlichung eine Telefonkonferenz und ein Unternehmensupdate um 8:30 Uhr ET folgen lassen.
Die Finanzergebnisse werden über eine Pressemitteilung auf der Website der Investor Relations des Unternehmens zugänglich sein. Interessierte Parteien können über einen Live-Webcast oder telefonisch an der Telefonkonferenz teilnehmen, wobei nationale Anrufer +1-800-717-1738 und internationale Anrufer +1-646-307-1865 verwenden können.
- None.
- None.
- Conference call to take place at 8:30am ET -
A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1-800-717-1738 or internationally +1-646-307-1865.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a development stage healthcare delivery company that intends to develop a best-in-class network of interventional psychiatry clinics to offer ketamine transcranial magnetics stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including risks arising from uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, HOPE Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund such acquisitions, and the Company's ability to spin-off HOPE Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-corporate-update-on-march-17-2025-302399503.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
When will NRXP release its Q4 and full year 2024 earnings?
How can investors access NRXP's Q4 2024 earnings call?
What time is NRXP's Q4 2024 earnings conference call?
Where can I find NRXP's Q4 2024 earnings press release?
